The global oligonucleotide synthesis market size was exhibited at USD 3.78 billion in 2023 and is projected to hit around USD 13.14 billion by 2033, growing at a CAGR of 13.27% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 4.28 Billion |
Market Size by 2033 | USD 13.14 Billion |
Growth Rate From 2024 to 2033 | CAGR of 13.27% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product & service, application, region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled | Thermo Fisher Scientific, Inc.; Merck KGaA; Danaher Corporation; Dharmacon Inc.; Agilent Technologies; Bio-synthesis; Kaneka Eurogentec S.A; LGC Biosearch Technologies; Biolegio; Twist Bioscience |
The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.
Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.
The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.
The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.
The market growth stage is high, and the market growth is accelerating. The oligonucleotide synthesis industry is characterized by a moderate to high degree of innovation due to rapid advancements in gene editing technology. Gene editing technology - Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is projected to be the most influential and innovative technology in biotechnology.
The oligonucleotide synthesis sector is further characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to gain access to new DNA & RNA facilities, increase their capabilities, expand product portfolios, and improve competencies.
The market is also subject to high regulatory scrutiny. Clinical applications of genomics face stringent monitoring and restriction in most countries, while some allow genetic research in sectors other than human use. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly.
The market has a moderate level of product/service expansion. This expansion involves introducing new types of oligonucleotides, improving synthesis technologies, and providing additional services to support customers. Service expansion involves offering comprehensive solutions, including synthesis, purification, and analytical services.
Regional expansion is a key factor with moderate to high growth in the market. Since several end-user industries are driving demand for oligonucleotide synthesis, the market players are investing in regional expansion to increase production capacity. Furthermore, regional expansion enables players to capture the untapped customer base, thereby contributing to the growth of the market.
The services segment dominated the market with the highest share of 38.0% in 2023 and is expected to witness the fastest growth during the forecast period. Certain factors, such as the growing use of molecular diagnostic tests and the higher adoption of oligonucleotide therapeutics, are expected to contribute to market growth. Moreover, key players are also broadening their offerings by entering new markets or acquiring service providers in different countries.
For instance, in November 2023, Twist Bioscience, a company specializing in synthetic biology and genomics, introduced Express Genes, a novel gene synthesis service with an expedited turnaround time of 5 to 7 business days. This service, conducted at the company's manufacturing facility in Wilsonville, Oregon, enables the swift production of genes.
The oligonucleotide segment is anticipated to grow at a significant CAGR during the forecast period. The increase in genomic studies, such as gene expression analysis and genetic testing, can be attributed to a substantial growth of the segment. In addition, introducing biochips (DNA chips) for parallel analysis of many clinical samples is anticipated to contribute considerably to the market’s revenue. With the growing usage of antisense oligonucleotides in clinical trials for conditions such as cancer, cardiac disorders, and ocular dysfunctions, the segment is anticipated to witness lucrative growth shortly.
Moreover, the growing awareness and understanding of genetic disorders contribute to the demand for oligonucleotides in diagnostics & potential therapeutic interventions. For instance, in August 2023, UC San Diego launched a Gene Therapy Initiative to develop innovative treatments for rare diseases, made possible by a USD 5 million donation from the Nancy and Geoffrey Stack Foundation.
The PCR primers segment held the largest market share in 2023. Primers are the most widely used oligonucleotide in PCR. They are part of sequences complementary to the 5’ end of the targeted sequence and are used for sequencing or amplification applications. The adoption of primers for gene sequencing experiments is increasing. Their use in fluorescent detection and target amplification has led to various primer designs with different probe- and primer-based detection chemistries. With technological advances, PCR has evolved, resulting in RT-PCR, qPCR, and digital PCR. PCR assays and panels are designed for detecting and measuring gene expression. The need for primers to suit the application of these enhanced systems for uses such as accurate quantification of gene expression is anticipated to fuel market growth.
The sequencing segment is anticipated to witness the highest CAGR during the forecast period. Sequencing applications are used to study various aspects of genomics and genetics. These applications involve the analysis of genetic material, such as DNA and RNA, to better understand the genetic makeup & function of organisms. Sequencing is crucial in identifying and tracking pathogens, particularly for emerging viruses and antibiotic-resistant bacteria. It necessitates rapid and accurate pathogen detection through oligonucleotide-based assays. Advancements in sequencing technologies and bioinformatics tools have also contributed to the growth of this market. In January 2023, QIAGEN acquired Verogen, specializing in NGS technologies, in a transaction worth USD 150 million. QIAGEN plans to integrate Verogen's technologies and talent into its existing operations.
North America dominated the global market with a revenue share of 41.0% in 2023. The large share is mainly attributed to many companies and research institutes creating high demand for oligonucleotides. For instance, in April 2021, DNAScript collaborated with Moderna along with a USD 5 million grant from the U.S. Defense Advanced Research Projects Agency. This collaboration was intended to develop a prototype for robust manufacturing of therapeutics and vaccines as part of the global nucleic acids on-demand program.
Asia Pacific is expected to witness the highest CAGR during 2024-2033. The growth is due to key players' growing interest in gaining higher profits in emerging markets. Players have adopted acquisitions, collaborations, and distribution agreements to gain a higher market share by increasing their revenue generation. Furthermore, Japan, China, and India, among other countries, are witnessing several business initiatives in the oligonucleotide synthesis market, thereby driving the regional market. For instance, in May 2023, GenScript Biotech Corporation expanded its primary manufacturing facility for oligonucleotide production in Jiangsu, China.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global oligonucleotide synthesis market.
Product & Service
Application
By Region
Chapter 1. Oligonucleotide Synthesis Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & service
1.2.2. Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Oligonucleotide Synthesis Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights
Chapter 3. Oligonucleotide Synthesis Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
3.2.1.4. Increased public-private spending on genomics
3.2.1.5. Technological advancements in gene editing technologies
3.2.2. Market restraint analysis
3.2.2.1. Need for advanced oligo synthesis solutions
3.2.2.2. High cost associated with genomics research
3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
3.3. Business Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis
4.1. Product & Service Market Share, 2024 & 2033
4.2. Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.2.1. Oligonucleotides
4.2.1.1. Market estimates and forecasts 2021 to 2033
4.2.1.2. DNA
4.2.1.2.1. Market estimates and forecasts 2021 to 2033
4.2.1.2.2. Column-based
4.2.1.2.2.1. Market estimates and forecasts 2021 to 2033
4.2.1.2.3. Array-based
4.2.1.2.3.1. Market estimates and forecasts 2021 to 2033
4.2.1.3. RNA
4.2.1.3.1. Market estimates and forecasts 2021 to 2033
4.2.1.3.2. By Technology
4.2.1.3.2.1. Column-based
4.2.1.3.2.1.1. Market estimates and forecasts 2021 to 2033
4.2.1.3.2.2. Array-based
4.2.1.3.2.2.1. Market estimates and forecasts 2021 to 2033
4.2.1.3.3. By Type
4.2.1.3.3.1. Short RNA Oligos (<65 nt)
4.2.1.3.3.1.1. Market estimates and forecasts 2021 to 2033
4.2.1.3.3.2. Long RNA Oligos (>65 nt)
4.2.1.3.3.2.1. Market estimates and forecasts 2021 to 2033
4.2.1.3.3.3. CRISPR (sgRNA)
4.2.1.3.3.3.1. Market estimates and forecasts 2021 to 2033
4.2.2. Equipment/Synthesizer
4.2.2.1. Market estimates and forecasts 2021 to 2033
4.2.3. Reagents
4.2.3.1. Market estimates and forecasts 2021 to 2033
4.2.4. Services
4.2.4.1. Market estimates and forecasts 2021 to 2033
4.2.4.2. DNA
4.2.4.2.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.2. Custom oligo synthesis services
4.2.4.2.2.1. 25 nmol
4.2.4.2.2.1.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.2.2. 50 nmol
4.2.4.2.2.2.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.2.3. 200 nmol
4.2.4.2.2.3.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.2.4. 1000 nmol
4.2.4.2.2.4.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.2.5. 10000 nmol
4.2.4.2.2.5.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.3. Modification services
4.2.4.2.3.1. Market estimates and forecasts 2021 to 2033
4.2.4.2.4. Purification services
4.2.4.2.4.1. Market estimates and forecasts 2021 to 2033
4.2.4.3. RNA
4.2.4.3.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.2. Custom oligo synthesis services
4.2.4.3.2.1. 25 nmol
4.2.4.3.2.1.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.2.2. 100 nmol
4.2.4.3.2.2.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.2.3. 1000 nmol
4.2.4.3.2.3.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.2.4. 10000 nmol
4.2.4.3.2.4.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.3. Modification services
4.2.4.3.3.1. Market estimates and forecasts 2021 to 2033
4.2.4.3.4. Purification services
4.2.4.3.4.1. Market estimates and forecasts 2021 to 2033
Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2024 & 2033
5.2. Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.2.1. PCR primers
5.2.1.1. Market estimates and forecasts 2021 to 2033
5.2.1.2. Academic research institutes
5.2.1.2.1. Market estimates and forecasts 2021 to 2033
5.2.1.2.2. Diagnostic laboratories
5.2.1.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.1.2.3. Pharmaceutical - biotechnology companies
5.2.1.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.2. PCR assays and panels
5.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.2.2. Academic research institutes
5.2.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.2.2.2. Diagnostic laboratories
5.2.2.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.2.2.3. Pharmaceutical - biotechnology companies
5.2.2.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.3. Sequencing
5.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.3.2. Academic research institutes
5.2.3.2.1. Market estimates and forecasts 2021 to 2033
5.2.3.2.2. Diagnostic laboratories
5.2.3.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.3.2.3. Pharmaceutical - biotechnology companies
5.2.3.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.4. DNA microarrays
5.2.4.1. Market estimates and forecasts 2021 to 2033
5.2.4.2. Academic research institutes
5.2.4.2.1. Market estimates and forecasts 2021 to 2033
5.2.4.2.2. Diagnostic laboratories
5.2.4.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.4.2.3. Pharmaceutical - biotechnology companies
5.2.4.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.5. Fluorescence in situ hybridization (FISH)
5.2.5.1. Market estimates and forecasts 2021 to 2033
5.2.5.2. Academic research institutes
5.2.5.2.1. Market estimates and forecasts 2021 to 2033
5.2.5.2.2. Diagnostic laboratories
5.2.5.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.5.2.3. Pharmaceutical - biotechnology companies
5.2.5.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.6. Antisense oligonucleotides
5.2.6.1. Market estimates and forecasts 2021 to 2033
5.2.6.2. Academic research institutes
5.2.6.2.1. Market estimates and forecasts 2021 to 2033
5.2.6.2.2. Diagnostic laboratories
5.2.6.2.2.1. Market estimates and forecasts 2021 to 2033
5.2.6.2.3. Pharmaceutical - biotechnology companies
5.2.6.2.3.1. Market estimates and forecasts 2021 to 2033
5.2.7. Other applications
5.2.7.1. Market estimates and forecasts 2021 to 2033
Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. North America
6.2.1. U.S.
6.2.1.1. Key country dynamics
6.2.1.2. Regulatory framework
6.2.1.3. Competitive scenario
6.2.1.4. U.S. market estimates and forecasts 2021 to 2033
6.2.2. Canada
6.2.2.1. Key country dynamics
6.2.2.2. Regulatory framework
6.2.2.3. Competitive scenario
6.2.2.4. Canada market estimates and forecasts 2021 to 2033
6.3. Europe
6.3.1. UK
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework
6.3.1.3. Competitive scenario
6.3.1.4. UK market estimates and forecasts 2021 to 2033
6.3.2. Germany
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. Germany market estimates and forecasts 2021 to 2033
6.3.3. France
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework
6.3.3.3. Competitive scenario
6.3.3.4. France market estimates and forecasts 2021 to 2033
6.3.4. Italy
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework
6.3.4.3. Competitive scenario
6.3.4.4. Italy market estimates and forecasts 2021 to 2033
6.3.5. Spain
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework
6.3.5.3. Competitive scenario
6.3.5.4. Spain market estimates and forecasts 2021 to 2033
6.3.6. Norway
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework
6.3.6.3. Competitive scenario
6.3.6.4. Norway market estimates and forecasts 2021 to 2033
6.3.7. Sweden
6.3.7.1. Key country dynamics
6.3.7.2. Regulatory framework
6.3.7.3. Competitive scenario
6.3.7.4. Sweden market estimates and forecasts 2021 to 2033
6.3.8. Denmark
6.3.8.1. Key country dynamics
6.3.8.2. Regulatory framework
6.3.8.3. Competitive scenario
6.3.8.4. Denmark market estimates and forecasts 2021 to 2033
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework
6.4.1.3. Competitive scenario
6.4.1.4. Japan market estimates and forecasts 2021 to 2033
6.4.2. China
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. China market estimates and forecasts 2021 to 2033
6.4.3. India
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. India market estimates and forecasts 2021 to 2033
6.4.4. Australia
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework
6.4.4.3. Competitive scenario
6.4.4.4. Australia market estimates and forecasts 2021 to 2033
6.4.5. South Korea
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework
6.4.5.3. Competitive scenario
6.4.5.4. South Korea market estimates and forecasts 2021 to 2033
6.4.6. Thailand
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework
6.4.6.3. Competitive scenario
6.4.6.4. Thailand market estimates and forecasts 2021 to 2033
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. Brazil market estimates and forecasts 2021 to 2033
6.5.2. Mexico
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Mexico market estimates and forecasts 2021 to 2033
6.5.3. Argentina
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Argentina market estimates and forecasts 2021 to 2033
6.6. MEA
6.6.1. South Africa
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. South Africa market estimates and forecasts 2021 to 2033
6.6.2. Saudi Arabia
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033
6.6.3. UAE
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. UAE market estimates and forecasts 2021 to 2033
6.6.4. Kuwait
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Kuwait market estimates and forecasts 2021 to 2033
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Merck KGaA
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Danaher Corporation
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Dharmacon Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Agilent Technologies
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Bio-synthesis
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Kaneka Eurogentec S.A
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. LGC Biosearch Technologies
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Biolegio
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Twist Bioscience
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives